Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:2.7.11.13 (
protein kinase C
)
49,245
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Endothelin (ET)-related peptides robustly stimulated [3H]-inositol phosphate (IP) formation in cultured cerebellar granule cells, astrocytes, and C6 glioma cells. Their agonist selectivities were ET-1 = ET-2 greater than or equal to sarafotoxin S6b greater than ET-3 greater than big ET-1 for granule cells and ET-1 greater than or equal to ET-2 greater than or equal to S6b greater than big ET-1 greater than ET-3 for cerebellar astrocytes and C6 glioma cells. These effects were Ca(2+)-dependent but insensitive to antagonists of L-type Ca2+ channels and the Na+/Ca2+ antiporter. Pretreatment of cells with ET-1 or S6b induced homologous desensitization of phosphoinositide (PI) response mediated by ET receptors. Long-term pertussis toxin (PTX) treatment attenuated the phosphoinositide (PI) response in astrocytes and glioma but not in granule cells. ET-1 and its related peptides increased [Ca2+]i in C6 glioma by two distinct pathways: IP3-induced Ca2+ mobilization or receptor-operated Ca2+ influx. La3+, Mn2+, and Cd2+ inhibited the Ca2+ influx and sustained PI turnover, while Ca2+ mobilization was attenuated by phorbol ester and TMB-8. ET-induced Ca2+ influx was essential for the sustained [Ca2+]i increase and PI turnover. Homologous desensitization of [Ca2+]i increase was also noted. In cerebellar granule cells, ET evoked the release of [3H]D-aspartate from these neurons. This action appears to be dependent on PI hydrolysis and [Ca2+]i increase and modulated by
protein kinase C
.
J
Cardiovasc
Pharmacol 1991
PMID:Endothelin-induced activation of phosphoinositide turnover, calcium mobilization, and transmitter release in cultured neurons and neurally related cell types. 172 40
In addition to its powerful vasoconstrictive activity, endothelin-1 (ET-1) is a potent agonist for stimulating a multitude of second messenger pathways. In the Rat-1 fibroblastic cell line, ET-1 induces a robust elevation of the intracellular levels of Ca2+, diacylglycerols (DGs), and inositol trisphosphate (IP3). Although low concentrations of ET-1 stimulate a significant increase in the rate of Ca2+ influx, this Ca2+ influx is not required for the observed increases in either IP3 or DG levels following ET-1 treatment, as both of these effects are observed even in the absence of extracellular Ca2+. The ability of ET-1 to stimulate Ca2+ influx shows a biphasic pattern, such that Ca2+ influx is stimulated at low ET-1 concentrations and inhibited at high concentrations. Investigations of the molecular mechanisms underlying this biphasic response indicate that elevated intracellular Ca2+ levels exert a negative feedback inhibition on Ca2+ influx, which can be relieved by the chelation of intracellular Ca2+. The ability of ET-1 to activate a number of distinct signal transduction pathways appears to have direct functional significance in determining the targeting of ET-1 activation. Short-term effects of ET-1 stimulation such as the induction of gene expression appear to be independent of ET-1's ability to activate
protein kinase C
(
PKC
) by elevating DG levels, as depletion of
PKC
activity has little or no effect on gene expression. In contrast, the ability of ET-1 to induce the rapid expression of the VL30 gene is totally dependent upon the ability of ET-1 to elevate intracellular Ca2+ levels above a specific threshold. Activation of
PKC
by ET-1, however, is essential for the long-term effects of ET-1 on cell proliferation and anchorage-independent growth, as the ability of ET-1 to promote DNA synthesis and to synergize with epidermal growth factor in augmenting anchorage-independent growth is significantly inhibited by prior
PKC
depletion. Thus, in fibroblasts, ET-1 appears to activate at least two bifurcating pathways: a Ca(2+)-sensitive pathway involved in the regulation of gene expression, and a
PKC
-dependent pathway required for the mitogenic effects of ET-1.
J
Cardiovasc
Pharmacol 1991
PMID:Regulation of intracellular Ca2+ and gene expression by endothelin-1. 172 41
At least two signal-generating systems are involved in the actions of various hormonal factors in human platelets--the adenylate cyclase system and the phosphoinositide-metabolizing pathway. The formation of cyclic AMP (cAMP) by the adenylate cyclase system--consisting of the catalyst itself, the Ns and Ni proteins, and various hormone receptors--is stimulated by prostaglandins and adenosine, and is inhibited by alpha 2-adrenergic agonists, ADP, vasopressin, platelet-activating factor, and thrombin. On the other hand, the formation of inositol trisphosphate and diacylglycerol by the phosphoinositide-metabolizing pathway is stimulated by some of the latter agents, particularly by thrombin. There are apparently several mutual interactions between these two signal-generating systems. On the one hand, increases in the level of cAMP inhibit the formation of inositol phosphates and diacylglycerol. It is presently unclear whether this inhibitory effect of cAMP is due to a direct action at the phospholipase C itself or to an indirect mechanism, for example, a depletion of the substrate of the enzyme. On the other hand,
protein kinase C
, which is activated by diacylglycerol, largely interferes with the adenylate cyclase system. This kinase, when activated by diacylglycerol or phorbol esters, apparently phosphorylates the guanine nucleotide-binding alpha-subunit of Ni, which results in an impairment or loss of the inhibitory hormonal signal transduction to the adenylate cyclase. Thus, available evidence indicates that the two signal-generating systems present in platelet membranes are not completely separated, and furthermore suggests that they may even be causally related to each other.
J
Cardiovasc
Pharmacol 1986
PMID:Interactions between the hormone-sensitive adenylate cyclase system and the phosphoinositide-metabolizing pathway in human platelets. 243 28
The effects of divalent cations on human platelet vasopressin receptor binding characteristics and effects of receptor occupancy on endogenous protein phosphorylation were investigated. Binding of vasopressin to its receptor is modulated by both the nature and the concentration of ions. Whatever the cation present, guanosine 5'-triphosphate or 5' guanylylimidodiphosphate do not alter the receptor binding characteristics. In the presence of extracellular calcium, vasopressin stimulates the phosphorylation of a 45,000-dalton protein and to a lesser degree of a 20,000-dalton protein following a pattern observed with thrombin and 12-O-tetradecanoylphorbol-13-acetate, a phorbol ester. Phosphorylation is also stimulated by a V1 vascular agonist, but not V2 renal agonists, and is more potently blocked by a V1 vascular antagonist than by a V2 renal antagonist. These results suggest that human platelets bear typical V1 vascular vasopressin receptors which stimulate the phosphorylation of specific substrates of
protein kinase C
and myosin light-chain kinase.
J
Cardiovasc
Pharmacol 1987 Jul
PMID:The human platelet vasopressin receptor and its intracellular messengers: key role of divalent cations. 244 Nov 50
We measured the amount of 1,2-diacylglycerol (DG) in rat hearts using thin-layer chromatography and a flame ionization detection technique, since 1,2-DG is thought to play a central role in the metabolism of phosphoinositide hydrolysis. In response to exogenous norepinephrine, a significant increase in 1,2-DG content in the myocardium was observed over 10-60 min, achieving an 80% increase over unstimulated controls at 60 min. On the other hand, the cholesterol content and six species of phospholipids were not significantly affected. In order to elucidate the mechanism of 1,2-DG accumulation elicited by norepinephrine, alpha- and beta-adrenergic antagonists were given. Pretreatment with phentolamine and prazosin, but not propranolol, inhibited the norepinephrine-induced 1,2-DG accumulation. Yohimbine appeared to have a partially inhibitory effect. These results suggest that myocardial norepinephrine-related 1,2-DG formation, which is likely to activate
protein kinase C
, is associated with alpha-adrenergic receptors, especially alpha 1-adrenergic receptors.
J
Cardiovasc
Pharmacol 1988 Jun
PMID:Sustained diacylglycerol formation in norepinephrine-stimulated rat heart is associated with alpha 1-adrenergic receptor. 245 59
Active tumor promoters such as 12-O-tetradecanoyl-phorbol-13-acetate (TPA) or membrane-diffusible synthetic diacylglycerols such as 1,2-dioctanoyl-sn-glycerol (DiC8), which specifically activate
protein kinase C
(
PKC
), inhibited the agonist-mediated rise in cytosolic calcium [(Ca2+)i] in a mast cell line (PB-3c) and human platelets. TPA inhibition of agonist-mediated calcium transient in platelets was readily reversed by the
PKC
inhibitor staurosporine. In contrast to DiCs, only active tumor promoters induced a time- and dose-dependent translocation of cytosolic
PKC
to membranes as determined both enzymatically or by immunoblotting. However, the concentration of TPA required to induce a half-maximal subcellular redistribution of immunodetectable
PKC
activity was an order of magnitude greater than the half-maximal dose required to inhibit the intracellular rise in (Ca2+)i. Thus, activation of
PKC
seems not to be exclusively coupled to its translocation to membranes, suggesting that translocation of
PKC
is mainly involved in the down-regulation of
PKC
. Down-regulation of immunoprecipitable
PKC
was studied in various human breast cancer cell lines that display differential growth inhibitory responses toward the tumor promoter. TPA induced translocation of [35S]methionine-prelabeled cytosolic 80 kDa
PKC
to membranes followed by complete degradation of the enzyme (t1/2 = 2 h) without affecting
PKC
synthesis. During prolonged TPA exposure, 20-80% of total 80 kDa
PKC
of control cells was still synthetized as a membrane-bound 74/80 kDa
PKC
doublet. Although both proteins lacked
PKC
activity and phorbol ester binding, they revealed structural similarity with the active 80 kDa
PKC
form of untreated cells.(ABSTRACT TRUNCATED AT 250 WORDS)
J
Cardiovasc
Pharmacol 1988
PMID:Role of protein kinase C (PKC) in short- and long-term cellular responses: inhibition of agonist-mediated calcium transients and down-regulation of PKC. 246 82
Preproendothelin-1 (ppET-1) mRNA has previously been demonstrated to be markedly induced in cultured endothelial cells (EC) by the addition to the medium of thrombin, an agent known to stimulate phosphoinositide turnover in EC. In this study, the mechanism of regulation of ppET-1 mRNA expression was investigated in cultured human umbilical vein EC by RNA blot analysis with cloned ppET-1 gene as a probe. The mRNA for ppET-1 was rapidly upregulated by O-tetradecanoylphorbol-13-acetate (TPA) (0.5 microM) and by ionomycin (5 microM) within 10 min of addition to the medium, but not by forskolin (50 microM). The rapid induction of ppET-1 mRNA by TPA or ionomycin occurred even in the presence of cycloheximide, indicating that the mRNA induction does not require de novo protein synthesis. The ppET-1 mRNA was an extremely unstable species of mRNA with an apparent half-life of about 15 min. However, the half-life of ppET-1 mRNA was not appreciably affected by TPA or ionomycin, suggesting that the mRNA induction by these agents is mostly due to an activation of the transcription of the mRNA. These observations indicate that the production of ET-1 in human EC can be controlled by a transcriptional gene regulation directly coupled to the intracellular signals from the phosphoinositide-turnover pathway, i.e., activation of
protein kinase C
and increase in intracellular Ca2+. These mechanisms are discussed in relation to information on the primary structure of cloned ppET-1 gene.
J
Cardiovasc
Pharmacol 1989
PMID:The human preproendothelin-1 gene: possible regulation by endothelial phosphoinositide turnover signaling. 247 87
Angiotensin II (Ang II) stimulation of vascular smooth muscle results in a myriad of intracellular signals that interact to produce the final physiologic response of the cell. One of the earliest documented events following incubation of these cells with Ang II is the rapid, phospholipase C-mediated hydrolysis of phosphatidylinositol-4,5-bisphosphate to yield two second messengers, inositol trisphosphate and diacylglycerol. Inositol trisphosphate releases calcium from nonmitochondrial intracellular storage sites, while diacylglycerol activates
protein kinase C
. Ang II also stimulates calcium influx and increases calcium efflux for the duration of the stimulus, as well as causing a biphasic change in intracellular pH. The delayed alkalinization is a consequence of enhanced Na+/H+ exchange. These signals then interact to modify the targets of phospholipase C, and result in phosphorylation of numerous cytoplasmic and cytoskeletal proteins. Thus, the signaling events induced by Ang II are complex, and dynamically interact to produce a constantly changing response for the duration of the stimulus.
J
Cardiovasc
Pharmacol 1989
PMID:Angiotensin II stimulation of vascular smooth muscle. 247 21
Differences in responsiveness of various vascular beds to pressor hormones have been reported. In our study, we have examined the effects of angiotensin II (Ang II) and vasopressin (AVP) on cytosolic free Ca2+ concentration [( Ca2+]c),
protein kinase C
(
PKC
) activity, and prostacyclin (PGI2) production in cultured aortic and mesenteric smooth muscle cells obtained from female Wistar rats. [Ca2+]c was determined using the Ca2+ fluorescent probe fura-2.
PKC
activity was assessed by the measurement of the phosphorylation of histone III-S, in the presence or absence of phospholipids, both in the cytosolic and particulate fractions. PGI2 production was estimated by a specific radioimmunoassay of its stable metabolite, 6-keto-PGF1 alpha. Our results demonstrate that basal production of PGI2 was higher in mesenteric than in aortic smooth muscle cells. In mesenteric cells, the [Ca2+]c,
PKC
activity, and PGI2 responses to AVP were higher than those induced by Ang II. This situation is the opposite of that observed in aortic smooth muscle cells. These results indicate different sensitivities to AVP and Ang II between vascular smooth muscle cells originating from two types of vessels.
J
Cardiovasc
Pharmacol 1989
PMID:Comparison of the effects of angiotensin II and vasopressin on cytosolic free calcium concentration, protein kinase C activity, and prostacyclin production in cultured rat aortic and mesenteric smooth muscle cells. 247 23
Class III antiarrhythmic agents may prolong refractoriness via modulation of ion channels, which may be sensitive to Ca2+ regulatory proteins or enzymes. Accordingly, the purpose of this study was to quantitate the effects of several structurally diverse class III antiarrhythmic agents on calmodulin-regulated enzymes and
protein kinase C
activity, and to evaluate the ability of these agents and known calmodulin antagonists to prolong cardiac refractoriness in vivo. The rank order of potency (IC50;microM) of selected class III antiarrhythmic agents and reference calmodulin antagonists as inhibitors of calmodulin-regulated phosphodiesterase activity were: calmidazolium (0.12 microM) greater than amiodarone (0.62 microM) greater than desethylamiodarone (1.5 microM) greater than trifluoperazine (4.3 microM), bepridil (5 microM) greater than W-7 (7.5 microM), clofilium (13 microM). Similar concentration-related inhibition was evident in a second calmodulin-regulated system, inhibition of myosin light-chain phosphorylation and superprecipitation of arterial actomyosin. Sotalol and tetraethylammonium were inactive at 100 microM. Protein kinase C activity was also inhibited by some of these agents; desethylamiodarone (IC50 = 11 microM) was more potent than the reference agent, H-7 (IC50 = 79 microM), or amiodarone (38% inhibition at 100 microM) and clofilium (32% inhibition at 100 microM). In vivo, the minimally effective doses required to increase ventricular effective refractory periods in paced guinea pigs were (in mg/kg) bepridil, sotalol [1] greater than clofilium [3] greater than amiodarone [10] greater than W-7, desethylamiodarone [20]. No changes in refractory period were noted with maximum testable doses of calmidazolium or trifluoperazine. These studies show that some, but not all, class III antiarrhythmic agents are effective and potent calmodulin antagonists or
protein kinase C
inhibitors. Moreover, some calmodulin antagonists are effective at prolonging refractoriness in vivo. However, a lack of correlation between these agents suggests that these mechanisms are not solely responsible for the prolongation of refractoriness of all class III agents.
Cardiovasc
Drugs Ther 1989 Oct
PMID:Inhibition of calmodulin and protein kinase C by amiodarone and other class III antiarrhythmic agents. 248 7
<< Previous
1
2
3
4
5
6
7
8
9
10
Next >>